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This paper has been prepared from the perspective of the ESRC Genomics Policy & 
Research Forum, which has the particular mandate of linking social science research 
on genomics with ongoing public and policy debates. It is intended as a contribution 
to discussions about the future agenda for social scientific analyses of genomics. 
Given its scope, this paper is necessarily painted with a broad brush. It is presented 
in the hope that it can serve both as a useful reference for those less familiar with the 
themes and foci of UK-based social science research about genomics and, for those 
more engaged in the field, as a foundation for discussions about the future social 
sciences agenda in this area. This paper has four parts. The first identifies the 
boundaries of the topic. It is suggested that the boundaries of genomics are properly 
regarded by social scientists as soft rather than hard, and as encompassing far more 
than genomics as narrowly understood. In the second part, the UK context for social 
science research is briefly described before proceeding to part three, which offers a 
survey of the major areas and patterns of research. This is organised by reference to 
the themes of globalisation, governance and regulation, and refers to 129 current or 
recently completed projects (surveyed during the winter of 2005) that address these 
themes. Part four proposes some appropriate areas for future research, drawing on 
and advancing what has been achieved thus far. Social scientific analyses of the 
nature and consequences of genomic science, it is claimed, have been crucially 
framed by the institutionalising of non-scientific considerations under the heading of 
ELSA/ELSI (Ethical, Legal and Social Aspects/Implications). It is suggested that an 
understanding of the limitations and consequences of this framing provides a vital 
starting point in considering future research agendas. 
 
Part I - The Boundaries of Genomics 
 
Whilst the much-celebrated completion of the sequencing of the human genome has 
given a certain familiarity in popular discourse to the word ‘genome’ (taken as 
signifying something to be understood as a sort of map or code of our genetic 
material), the word ‘genomics’ has gained much less currency and still less any 
depth of understanding. But even where there is a recognition of the term, there is 
often an uncertainty about its meaning and use. It was the experience of the 
Genomics Forum, in inviting a wide range of interested participants to meetings to 
discuss issues in human, animal and plant genomics, that even (perhaps especially) 
amongst interested parties, the use of the term ‘genomics’ is problematic. 
 
Natural scientists understood the term, reasonably enough, to refer to a set of 
techniques or technologies specifically to do with the mapping or sequencing of 
genomes. In addition they associated genomics with ‘post-genomic’ disciplines (such 
as proteomics or metabolomics) and with developments of the quantitative and 
computational tools needed to exploit the vast amounts of data generated by 
sequencing technologies. Participants with different backgrounds and with different 
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interests (including policy-makers, members of civil society organisations, and social 
scientists) tended to use the term ‘genomics’ more loosely to signify something that 
might be called ‘genetic technologies’. In this latter usage, ‘genomics’ was not 
sharply distinguished from, for example, genetically modified (GM) crops, genetic 
modification more broadly, gene therapy, genetic testing, cloning, xeno-
transplantation and even the use of stem cells. On occasions—and particularly, it 
seemed, where there was a fear that the controversy surrounding GM might 
somehow become attached to genomics unless the distinction were maintained—
natural scientists found it necessary to try and maintain the more limited usage of the 
term ‘genomics’ and to complain of a risk of confusion. They pointed out, for 
example, that genomics and genetic modification are two distinct things, in the sense 
that the mapping and sequencing of genomes proceeds independently of genetic 
modification, and vice versa; there was plainly genetic modification before there was 
genomics, and there could be genomics whether or not there is genetic modification. 
This insistence on difference and discontinuity is, of course, also part of the wider 
presentation of the development of genomics as constituting a revolution in the 
biological sciences. 
 
In understanding the scope of the social science of genomics (and thus the concern of 
this paper) it is important to recognise both the merit of the natural scientists’ rather 
precise usage, but also why the looser use of the term and the regular association of 
genomics with a range of other technologies points to something important about 
these scientific developments. The contrast between these two connotations of 
‘genomics’ bears some elaboration. 
 
If the genome is thought of as the totality of genetic material that provides the code 
which makes us what we are, then genomics is the science of this totality. By means 
of tools of mapping, sequencing and analysis of genetic material as a totality, 
genomics seeks an understanding of the functions and interactions of this genetic 
material and thus an understanding of the biology of organisms. 
 
Understood in this way, the term ‘genomics’ refers us to the very specific scientific 
developments which led to and were advanced by the high-profile mapping projects 
which captured public attention. Even understood in this narrow sense, genomics 
opens up a rich field for social scientific reflection and analysis. The sequencing of 
the human genome was a major international programme of research and 
cooperation which involved huge effort and resources and which commanded 
considerable financial and political support, as well as significant media and public 
attention. The processes and institutions which shaped and were shaped by this 
scientific endeavour are quite properly the subject of investigation, as are the 
implications of genomics for understandings of what it is to be human, and a human 
individual. 
 
If this, however, identifies the scope of genomics from a scientific viewpoint, those 
at the Forum’s meetings who understood genomics less precisely, or who 
immediately associated genomics with a wide range of other biotechnologies, should 
not simply be disregarded as mistaken. ‘Genomics’, understood in the narrow sense, 
is a range of techniques and technologies which enable us better to understand and 
hence to engage with living organisms. It is, if you like, a tool (or set of tools) which 
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increases our power to understand, and hence to affect, shape or manipulate the 
natural world. Thus, though it should not be confused with biotechnology in general, 
or genetic modification or stem cell research in particular, the tendency of popular 
discussions to link these separate activities indicates something of great 
importance—for the very sense of interest and high excitement around genomics is 
just that this tool increases the power of the other tools of biotechnology. Thus, 
though it is undeniable, for example, that there was genetic modification before there 
was genomics (and that one could pursue genomics while eschewing genetic 
modification), genomics enables scientists to make genetic modification more 
efficient and effective (although, arguably, it may also render GM otiose). Genomics 
is not genetic modification, but the linking of the two is not straightforwardly wrong. 
A hammer is not a chisel, and there may have been hammers before there were 
chisels, or vice versa; but the social significance of these two tools could hardly be 
comprehended were their study to be sharply differentiated. 
 
When this is understood, it can be seen that the proper scope of the study of 
genomics for social science is much wider (and less easily bounded) than would be 
the study of genomics as understood by many natural scientists as an important but 
discrete field of contemporary science. Genomics is a tool, which has arisen from the 
advances in biology and genetics that span the fifty years from the discovery of the 
structure of DNA in 1953 to the sequencing of the human genome in 2003. It is a 
part of this story and intimately connected with the other elements of it, 
conceptually, practically and in popular thought and discourse. It is related to, and 
has implications for, all those things which are often connected with it, such as GM 
crops, genetic modification more broadly, gene therapy, genetic testing, cloning, 
xeno-transplantation, the use of stem cells and so on. Social science will be 
concerned to understand what is significant and important about genomic science 
narrowly construed; but it would be guilty of ignoring the wider context of meaning 
and significance in which genomics has been developed and which it has the power 
to affect and transform, if it concerned itself with the field as narrowly identified for 
the purpose of demarcating the specialisms of contemporary biology. 
 
Part II - The UK Context 
 
A substantial amount of time, money and energy has been invested in the UK in 
social scientific research relating to genomics. This has been co-ordinated principally 
through Universities, associated think-tanks, and a wide range of funding bodies. 
The Economic and Social Research Council (ESRC) is a core UK funder of social 
scientific research and has sponsored a wide range of genomics-related activities. 
This commitment has been reviewed elsewhere.1 For the purposes of this paper, most 
relevant is the ESRC Genomics Network (EGN), a £12.5 million investment which 
comprises the research centres Cesagen (Universities of Cardiff and Lancaster), 
Egenis (University of Exeter), and Innogen (University of Edinburgh and the Open 
University), as well as the ESRC Genomics Policy and Research Forum and ESRC 
Attitudes to Genomics Survey. The ESRC has also sponsored two research 
programmes, Science in Society and Innovative Health Technologies, which in turn 
have funded many projects relevant to analyses of genomics in society.2 Other 
funding bodies which have invested heavily in research on genomics and society 
include the Wellcome Trust, the Leverhulme Trust and the European Commission.3 
© ESRC Genomics Network.
            Genomics, Society and Policy 




Genomics, Society and Policy, Vol.2 No.2 (2006) ISSN: 1746-5354 
 
 
In addition to the centres of the EGN, several UK research institutes have run or are 
running programmes related to genomics and society. These include the Science and 
Technology Studies Unit (SATSU) at the University of York; The Institute for the 
Study of Genetics, Biorisks and Society (IGBiS) at the University of Nottingham; 
The Policy, Ethics and Life Sciences Research Centre (PEALS), a partnership 
between the Universities of Durham and Newcastle and the Centre for Life; The 
BIOS Centre of the London School of Economics; and the Science & Technology 
Research Unit (SPRU) at the University of Sussex. Further, the Nuffield Council on 
Bioethics, the Oxford Centre for Ethics and Communication in Health Care Practice 
(Ethox), sponsored by the Ethox foundation, and the University of Cambridge Centre 
for Medical Genetics and Policy (CMGP), associated with the Cambridge Genetics 
Knowledge Park, conduct research relevant to genomics and society. 
 
Thus the UK is host to a wide range of research centres, funding bodies, and 
academic units focussed on the social and policy aspects of genomics research. 
Collectively, these centres have conducted an extensive amount of research seeking 
to understand how, and whether, the advent of genomics and post-genomics research 
is fundamentally altering society. The following section seeks to draw upon as much 
of this research as possible whilst remaining coherent and concise. 
 
Part III - Genomics and Social Science: A Survey of Current Research in 
Genomics in the UK 
 
Our current epoch is often characterised as one of radical and transformative change 
in which boundaries—between state and society, global and local, even between the 
natural and unnatural—become increasingly blurred. Genomics has been developed 
and will continue to develop in this context of change, and will itself be shaped by, 
and contribute to, further transformations. 
 
This section summarises some of the recent UK-based research that has devoted 
itself to elucidating and understanding such transformations. It is organised with 
reference to three broad themes: globalisation, development and genomics; 
governance, publics and genomics; and regulation, innovation and genomics. These 
themes were selected after the research projects reviewed for this paper (see Table 1 
below4) were analysed according to their empirical and theoretical focus and 
principle research questions. The desire was to classify the projects with reference to 
a limited number of themes in order to appropriately represent individual projects 
whilst also encompassing the vast array of research surveyed in this paper. Thus the 
classification of projects according to the aforementioned themes is best viewed of as 
‘fluid’: the themes provide a context for, and means of organising, this survey of 
current UK-based social science research engaging genomics and the broader range 
of biotechnologies from which it has arisen and with which it is associated.5 
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Table 1. Ongoing and Recently Completed UK Research in the Social Science of 
Genomics 
 
Project Institute Project Project Leader(s) 
1 University of Dundee  A new geography of health: transforming 
heart disease in the new genetics era  




Action research to develop IEC materials 
that support informed consent processes 
for research in developing countries. 
Catherine S. 
Molyneux  
3 Cesagen Indigenous Peoples Brian Wynne 
4 Innogen Genomic and biotechnology partnerships 
in Africa 
Joanna Chataway 
5 Innogen Genomics and biotechnology partnerships 
in less developed countries 
Joanna Chataway 
6 Innogen Institutional Impacts of North-South 
partnerships in agricultural biotechnology 
Jane Bower 
7 Cesagen (In part of 
collaboration) 
Genomics and Benefit Sharing with 
Developing Countries (BeSha) 
Ruth Chadwick 
8 Cesagen (In part of 
collaboration with 
Centre for Science, 
Society and 
Citizenship in Rome) 
Bioethical Implications of Globalisation 
Processes (BIG) 
Ruth Chadwick 
9 Egenis The impact of advanced genomics-based 
tools for agronomy, plant breeding and 
food production on local agricultural 
practices 
Steve Hughes 
10 University of East 
Anglia 
The global politics of human embryonic 
stem cell regulation 
Brian Salter 
11 SPRU, University of 
Sussex 
Report production on the latest trends of 
Life Science and Biotechnology in Europe 
Nick von 
Tunzelmann 
12 University of 
Cambridge: Centre 
for Business Research  
Corporate responses to macroeconomic 
changes and shocks  
M. Kitson  
13 Cardiff University, 
Watt University, 
University of Wales 
College of Medicine  
Genetic testing and insurance: the 
problem of adverse selection  
Lindsay Prior  
14 Cesagen The economics of innovation in genomics Phil Cooke 
15 University of Leeds Social And Ethnic Differences In 
Attitudes And Consent To Prenatal 
Testing  
Jenny Hewison 
16 University of 
Cambridge  
Informed consent and genetic data  Dr Onora O'Neill  
17 School of Nursing & 
Midwifery, King's 
College London 
Facilitating choice, framing choice: the 
experience of staff working in 
preimplantation genetic diagnosis.  
Clare Williams  
18 IGBiS (Nottingham) Genetic Counselling for 
Haemochromatosis 
Melanie Pearce 
19 Genetic Interest 
Group and University 
of Southampton 
The Human Rights Act and genetics  Mr John Gillott 
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Project Institute Project Project Leader(s) 
20 University of Bristol Ethical protection in epidemiological 
genetic research: participants' perspectives  
Alastair Campbell  
21 BIOS (LSE) Genome-based Therapeutic Drugs for 
Depression (GENDEP) 
Ilina Singh 





University of London 
Ethical issues in the collection of 
pregnancy-related tissue samples  
Naomi Pfeffer, 
Donna Dickenson  
23 IGBiS (Nottingham) Mothers' Responses to the Possibility of 
Pre-Implantation Genetic Modification of 
their Babies  
Susan Johnson 
24 Centre for Ethics in 
Medicine, University 
of Bristol; Institute of 
Ethics and Law in 
Medicine, University 
of Glasgow 
Scoping Study: Ethical and practical 





25 King's College, 
University of London  
Informed consent in Sri Lanka: Current 
practices, quality of the information 




26 Institute of Law & 
Ethics in Medicine, 
University of 
Glasgow 
Ethico-legal governance in healthcare.  Sheila Mclean 
27 University of 
Cambridge 
From the corporeal to the informational: 
recent transformations in the constitution 
of collections of human biological 
materials and their implications for access 
and use  
Bronwyn Parry  
28 PEALS Ordinary Ethics: moral evaluation of the 




The Institutionalisation of Ethics in 
Science Policy: Practices and Impact 
(INES)  
Ruth Chadwick 
30 Department of 
Sociology, University 
of Exeter 
Accountability and the governance of 
expertise: anticipating genetic bioweapons 
Brian Rappert 
31 Mountbatten Centre 
for International 
Studies, University of 
Southampton 
Science, Security and Regulation: How 
effective are export controls? 
Jez Littlewood 
32 SPRU, University of 
Sussex 
Dual use controls and genomic research Paul Nightingale 
33 IGBiS (Nottingham) Representations of Complexity in Policy 
Networks 
Ian Forbes 
34 University of 
Leicester 
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Project Institute Project Project Leader(s) 
35 Innogen (University 
of Edinburgh) 
Legal and bioethical regulatory 
mechanisms 
Graeme Laurie 
36 Cesagen Genetic Databases Ruth Chadwick 
37 Dept of Sociology & 
Social Policy, 
University of Durham 
Forensic DNA databasing: A European 
perspective 
Robin Williams  




Policy issues in the evaluation of clinical 
genetic testing  
David Melzer, Ron 
Zimmern, Simon 
Sanderson  
39 University of East 
Anglia 
Reforming the Governance Of Human 
Genetics: The Politics Of Public Trust 
Brian Salter 
40 Innogen (University 
of Edinburgh) 
The national and international policy 
environment for genomics 
Joyce Tait 
41 IGBiS (Nottingham) The Politics of Food Brigitte Nerlich 
42 Innogen Interests and values in risk-related 
stakeholder interactions 
Joyce Tait 
43 SATSU, York 
University 
Quality assured science: the role of 
standards in stabilising stem cell research 
Andrew Webster 
44 University of Durham 
and University of 
Nottingham 
Genetic information and crime 
investigation: social, ethical and public 
policy aspects of the establishment, 
expansion and police use of the National 
DNA Database (NDNAD)  
Robin Williams, 
Paul Martin 
45 University of 
Lancaster (IEPPP) 









46 Innogen (The Open 
University) 
Trading up environmental standards? 
Trans-Atlantic governance of GM crops  
D. Wield, Susan 
Carr 
47 University of 
Birmingham 
The politics of GM food  David Marsh 
48 University of 
Cambridge 
Information policy for pharmacogenetics  David Melzer  
49 University of Oxford Governing genetic databases Michael Parker 
50 Cardiff University The clinical picture: the interaction of 
clinical medicine and genetic technology  
J. Latimer 
51 University of Oxford Ideas, experts and the politics of eugenics: 
a comparative and historical analysis  
Desmond King  
52 University of 
Edinburgh / York 
University (SATSU) 
Transformations in Genetic Subjecthood  Sarah 
Cunningham-
Burley, Anne Kerr 
(now at University 
of Leeds) 
53 IGBiS (Nottingham) Exploring the implications of using race/ 
ethnicity in applied population genetics 
Paul Martin  
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Project Institute Project Project Leader(s) 
54 Cardiff University Genetics, religion and identity : a study of 
Bangladeshi Muslims in Britain  
S. Gilliat-Ray  
55 Queen Mary: 
University of London 
Genealogy and genetics : cultural 
geographies of relatedness  
Catherine Nash 
56 SPRU, University of 
Sussex 
The Patenting of Human DNA: Global 
trends in commercial and public sector 
activity 
Sandra Thomas 
57 University of 
Warwick 
The evolution of biomedical knowledge : 
interactive innovation in the UK and US  
Jacky Swan 
58 IGBiS (Nottingham) Genetic Testing Robert Frost, Paul 
Martin 
59 Innogen The public and private organisation of 
genetic information 
David Wield 
60 IGBiS (Nottingham) / 
SPRU 
The Impact of Genomics on Innovation in 
the Pharmaceutical Industry  
Paul Martin, Paul 
Nightingale 
61 University of 
Cambridge: Centre 
for Business Research 
Commercializing science : entrepreneurial 
UK genomics firms in comparative 
perspective 
S. Casper 
62 Cesagen Transcending the genome: the paradigm 
shift to proteomics 
Peter Glasner 
63 Innogen Genomics Innovation in Scotland Jane Bower 
64 Innogen Innovation processes in genomics industry 
sectors 
Joyce Tait 
65 Centre for Economic 
Policy Research 
GM foods: facts, mergers, business 
practices and intellectual property  
P. Regibeau, K.E. 
Rockett  
66 Cesagen Plant Genomics, Commercialization and 
Environmental Knowledge: Shifting 
cultures of scientific research 
Brian Wynne, 
Claire Waterton 
67 SATSU, York 
University 
Pharmacogenomics, diagnostic tests and 
clinician acceptance 
Graham Lewis 
68 IGBiS (Nottingham)/ 
SATSU 




Graham Lewis  
69 SATSU, York 
University/ SPRU 
Pharmacogenetics and 
pharmacogenomics: State-of-the-art and 
potential socio-economic impact  
Graham Lewis 
70 Goldsmiths College, 
University of London 
and University of 
Wales College of 
Medicine 
Ethical factors in psychiatric drug 
development: an archival study of the 
ethical factors that influenced the 
development and production of Prozac in 
Eli Lilly & Company Ltd  
Mariam Fraser, 
Nikolas Rose, 
David Healy  
71 Institute for the Study 




Caught between science and society: food 
and mouth disease 
Brigitte Nerlich 
72 Cesagen Definitions Of Genetic Knowledge & Pre-
Implantation Genetic Diagnosis: An 
Ethnographic Study 
Sarah Franklin 
(now at LSE) 
73 Warwick University Social Implications Of One Stop First 
Trimester Prenatal Screening 
Gillian Lewando-
Hundt 
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Project Institute Project Project Leader(s) 
74 Cesagen The emerging politics of new genetic 
technologies: the organisation, 
mobilisation and inclusion of public 
voices in the regulation of cutting edge 
science 
Ian Welsh, Robert 
Evans 
75 Centre for 
Environmental Risk, 
University of East 
Anglia 
Public Perceptions of Risk, Science and 
Governance 
Nick Pidgeon 
76 The Open University Farmers' Understandings of genetically 
modified crops within local communities 
Andy Lane 
77 University of Cardiff Inside or outside the bioscience tent? The 
presentation of laboratory-self 
A. Erkisson 
78 University of 
Liverpool/ SATSU, 
York University 
Variability in response to warfarin: a 
prospective analysis of pharmacogenetic 
and environmental factors  
Munir 
Pirmohamed, 
Andrew Webster  
79 Cesagen Factors affecting preimplantation genetic 
diagnosis (PGD) patient's attitudes toward 
donation of embryos for stem cell research 
Sarah Franklin 
(now at LSE) 
80 Department of 
Anthropology, 
University of Sussex 
Childhood vaccination: science and public 
engagement in international perspective 
James Fairhead 
81 SPRU, University of 
Sussex 
Deliberative Mapping: Piloting an 
Innovative Public Consultation Process 
with the Case of Xenotransplantation and 
Organ Failure 
Andy Stirling 
82 Cardiff University Collective learning in knowledge 
economies: milieu or market?  
Philip Cooke 
83 SPRU, University of 
Sussex 
Public Perceptions of BSE and CJD Risk 
in Europe, their interplay with Media, 
Policy Initiatives and Surveillance Issues 
Erik Millstone 
84 IGBiS (Nottingham) Decision-Making by Women At-Risk of 
Hereditary Breast And Ovarian Cancer 
Emma Rowley 
85 PEALS Cumbria Genetics Database Erica Haimes 
86 IGBiS (Nottingham) The Regulation of DNA Databases Paul Martin 
87 University of 
Liverpool 
How do users interpret probabilistic 
pregnancy screening information?  
R. S. Bramwell, 
88 IGBiS (Nottingham) The Rhetoric of Genes Craig Hamilton 
89 Cesagen Explanation in genetics: causality and 




90 University of Surrey Attitudes to genomics (Genomics survey) R. Shepherd  
91 University of Surrey Public understanding of genomics and the 
dynamics of attitude change  
P. Sturgis 
92 IGBiS (Nottingham) The role of imagery and emotions in 
decisions concerning GM food 
Ellen Townsend 
93 PEALS A comparative study of embryo donors’ 
and non-donors’ views on embryo 
experimentation for preimplantation 
genetic diagnosis and stem cell therapy  
Erica Haimes, 
Alison Murdoch 
94 IGBiS (Nottingham) New Social Movements, Popular Media 
and Policy-Making 
Paul Martin 
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Project Institute Project Project Leader(s) 
95 IGBiS (Nottingham) Patients' constructions of familial 
hypercholesterolaemia 
Kate Weiner 
96 Cesagen Genetics, Health and Identity Angus Clarke, 
Srikant Sarangi 
97 Egenis The relationships between theories of 
groups memberships and inter-group 
attitudes 
Thomas Morton 
98 Innogen Talking about stem cells: The Social 








99 Egenis Complex Risks and Testing for 





Xenotransplantation: Risk Identities and 
the Human / Non Human Interface  
Mike Michael 
101 SPRU, University of 
Sussex 
Chemical / Biological Warfare Julian Perry 
Robinson 
102 IGBiS (Nottingham) The Regulation of Small Biotech Start-Up 
Companies in Scotland and Norway 
Robert Dingwall 
103 SPRU, University of 
Sussex 
Study on benchmarking of public 
biotechnology policy 
Pari Patel 
104 Cardiff University The Construction Of Risk Estimates In A 
Cancer Genetics Clinic  
Lindsay Prior 
105 Cesagen Genetic Screening For Susceptibility To 
Disease: The Case Of Haemochromatosis  
Paul Atkinson 
106 Brunel University The impact of genetic risk information on 
families of Pakistani origin referred for 
genetic counselling  
Alison Shaw, Jane 
Hurst 
107 University of Sussex The ethical and public policy implications 
of the new genetics and transgenics in the 
carcinogenic risk assessment of 
pharmaceuticals  
John Abraham 
108 King's College, 
University of London 
Mapping stem cell innovation in action Clare Williams 
109 University of the 
West of England 
Forgotten Fetuses - A Sociocultural 
analysis of the use of fetal stem cells 




Haematopoietic Stem Cells: The 
Dynamics of Expectations in Innovation 
Paul Martin, Nik 
Brown 
111 Cardiff University Medical Device Governance: Regulation 
of Tissue Engineering in the UK and EU  
Alex Faulkner 
112 IGBiS (Nottingham) The Regulation of Cloning Paul Martin 
113 University of 
Edinburgh 
Health, life insurance and financial 
inclusion  
P.G. Bennett 
114 IGBiS (Nottingham) Popular Media and the Production of 
News about Biorisk: 
'Health risks, body risks and food 
presentation in women’s general interest 
Kathy Wilkinson 
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Project Institute Project Project Leader(s) 
magazines’ 
115 University of 
Plymouth 
Nanotechnology and news production : 
scientists', journalists’, and editors' views  
A. Anderson  
116 University of 
Nottingham 
Implicit models of evolution in broadcast 
wildlife and nature programmes  
M.E. Alridge, 
Robert Dingwall  
117 Cesagen Communicative frames in counselling for 
predictive testing  
Srikant Sarangi, 
Angus Clarke 
118 IGBiS (Nottingham) The meaning of genetics - a project based 
on corpus linguistics 
Craig Hamilton 
119 IGBiS (Nottingham) Genomics Discourse - Special Journal 
Edition of Discourse & Society 
Brigitte Nerlich 
120 University of Reading The presentation of GM crop research to 
non specialists: a case study  
G. Cook, P.T. 
Robbins  
121 University of Reading  The discourse of the GM food debate: 
how language choices affect public trust 
G. Cook, P.T. 
Robbins, E. Pieri 
122 Egenis Genomics as a Source of Status Markers Barry Barnes 
123 Egenis The Cultural History of Heredity Staffan Mueller-
Wille 




125 Cesagen Media, Culture and Genomics Jenny Kitzinger, 
Maureen McNeil 
126 Egenis Patenting and the utility of genomic 
knowledge 
Jane Calvert 
127 University of Exeter Ambiguity and optimism  David Kelsey 
128 University of York Doing embryo ethics: safety and efficacy 
in research and practice 
Anne Kerr (now at 
University of 
Leeds) 
129 Cesagen Reconfigurations of Human/Animal 






(i) Globalisation, Development and Genomics 
 
In the 1960’s, Marshall McLuhan coined the term ‘global village’ when analysing 
the effects of the increased interconnectivity of global society through information 
technology.6 Four decades later, globalisation has occurred not only through the 
compression of space and time by information technology but also via 
unprecedented levels of cross-border cultural and economic exchange. 
 
Central to globalisation has been the reduced power of individual nation-states over 
global and domestic politics, economics and culture, as well as the rise of entities 
such as trans-national corporations, public-private partnerships, NGOs or the supra-
governmental European Union. The rise of these organisations has profoundly 
influenced the way in which societies are governed (as will be further discussed in 
III (ii)). Some also argue that globalisation’s ‘new world disorder’7 has lead to 
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greater disparity between rich and poor, northern and southern countries. As some 
feel increasingly empowered, others feel disempowered. Whether globalisation tends 
towards such polarisation is an open question; but disputes over the global 
commercialisation of genetically modified organisms (GMOs), for example, may be 
seen as indicative of the tensions created by globalisation: 
 
‘Globalisation…connotes, at one extreme, confident utopian 
fantasies of omnipotence, and at the other, a sense of things falling 
apart, of centres that do not hold, and of a radically diminished 
sense that one’s voice, one’s actions, or even one’s existence matters 
or makes a difference to the way things are. And perhaps nowhere is 




Thus studies of globalisation are aided by examining the social, political and 
economic issues surrounding biotechnology, and vice versa. This applies across the 
world, but arguably, the most urgent issues created by globalisation centre around 
the economic and health impacts on people in developing countries.9 Studies of 
‘development’, which suggest that technologies including biotechnologies have 
played a central but controversial role for the past half-century,10 are thus highly 
relevant and properly address the present and future implications of genomic science. 
 
Focal points for such studies include analyses of the capacity of developing nations 
to research, develop, apply and/or govern biotechnologies.11 Moreover, building 
developing countries’ capacities to assess for themselves the risks and benefits that 
biotechnologies pose is another important issue related to development. Of course 
not all such countries may be grouped together, as they have widely varying 
expertise in employing biotechnologies. However, in the context of development, 
biotechnologies remain highly controversial. Industrialised countries have, 
notoriously, had difficulties in establishing regulatory systems to govern the risks 
that biotechnologies may pose and in coming to consensus (nationally and 
internationally) on which biotechnologies should or should not be permissible; the 
challenges for more newly industrial countries, yet to develop biotechnology sectors, 
are likely to be more acute. 
 
UK Research Addressing Globalisation, Development and Genomics 
 
Of the research programmes listed in Table 1, a relatively minor proportion are 
devoted to issues directly related to globalisation and development.12 Most 
concentrated are a series of projects within the ESRC Genomics Network (Innogen, 
Cesagen, Egenis), which are broadly exploring how ‘modern biotechnology can be 
translated into practice’ given many constraints, such as lack of infrastructure, lack 
of ‘capacity’, and political and economic obstacles to technology transfer.13 These 
projects comprise a critical analysis of the types, characteristics, operations and 
impacts of various development public and/or private initiatives.14 The diffusion of 
knowledge/technology and its flow between various actors (e.g. scientists, farmers, 
businesspeople) is an important theme in this research. Another important theme is 
the rights of local populations, such as indigenous people in the Amazon, where one 
project is aimed at understanding the Amazonian perspective to inform policy 
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debates about issues such as indigenous peoples’ rights, prior informed consent or 
benefit-sharing.15 
 
Other research programmes, concerned with the dangers posed by the globalisation 
of biomedical R&D, focus on the potential exploitation of those used as subjects for 
research or as donors of biological materials. Whilst these projects are not focussed 
on issues arising solely from genomic research and medicine, the promise of 
genomic medicine and the globalisation of R&D makes these enquiries highly 
pertinent to this report. Research at Cesagen is seeking to identify and anticipate 
some of the key bioethical implications of globalisation processes.16 Two projects 
sponsored by the Wellcome Trust are analysing current practices in specific 
developing countries aimed at seeking informed consent, and how these practices 
might be enhanced and supported.17 This builds upon earlier research such as the 
2002 report, The Ethics of Research Related to Healthcare in Developing Countries, 
published by the Nuffield Council on Bioethics, in drawing attention to the 
challenges in ensuring that globalisation of technology is sensitive to issues of justice 
as they occur in specific and local contexts.18  
 
(ii) Governance, Policy, Publics & Genomics 
 
As discussed above, globalisation processes have arguably contributed to an 
alteration in the role and power of nation-states. This alteration has been so 
profound, it is suggested, that government (in the sense of the formal exercise of 
executive powers by regularly constituted political authorities) is no longer the 
determinant of public affairs. Where the state is hollowed out,19 room has been 
created for more actors to emerge. The boundary between state and society has 
blurred: 
 
‘…no single agency, public or private, has all the knowledge and 
information required to solve complex problems in a dynamic and 
diverse society, and no single actor has the power to control events 
in a complex and diverse field of actions and interactions.’
20 
 
In this state of affairs: 
 
‘…social-political governance and governing are not primarily 
looked upon as acts of governments, but as more or less continuous 
processes of interaction between social actors, groups and forces 




The term ‘governance’ is used to mark this ‘change in the meaning of government’ 
and to refer ‘to the new method by which society is governed.’22 
 
In these circumstances, national governments no longer dictate policies so much as 
steer them. One of governments’ key roles within governance becomes then, to 
create a forum in which policy-making can occur and decisions taken. Within this 
forum, transient and unforeseen alliances tend to mobilize around specific issues, 
creating loose and ad hoc policy networks.23 But just as there is ‘a multitude of 
autonomous actors who create patterns of structured cooperation despite the absence 
of a central organizing authority’,24 so there is, in fact, a multitude of fora in which 
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they act and engage. If ‘governance is about the ways and means in which the 
divergent preferences of citizens are translated into effective policy choices, about 
how the plurality of social interests are transformed into unitary action and the 
compliance of actors is achieved’,25 then it must account for a transformation which 
emerges from numerous overlapping and competing fora, including regional and 
national governments, the European Commission, international agencies and 
authorities (e.g. OECD, UNESCO, GATT, the Cartagena Protocol on Biodiversity) 
and so on. 
 
The Governance of Genomics 
 
The plurality of actors involved in governance has great significance for genomics. 
Biotechnologies, like other new bodies of knowledge, carry within them the 
‘potential for new forms of power, regulation and surveillance. Professing to offer 
new ways to reproduce and “improve” our bodies, our minds and our environments, 
such techniques raise new questions about the nature of human existence and the 
type of social relationships we want to perpetuate.’26 These questions are profoundly 
difficult, and their resolution is certainly rendered no easier by the wide range of 
actors or stakeholders who are implicated in contemporary patterns of governance, 
with its multiple fora. Consequently systems of governance—and within them, 
regulatory systems, which are often at the forefront of debates surrounding 
biotechnology27 (as will be discussed in III (iii))—are placed under enormous strain 
as they confront these issues. 
 
Salter and Jones have helpfully summarised some of the critical challenges related to 
the governance of the ‘new’ genetics: 
 
‘Civil society, science and industry all have a political interest in the 
creation of human genetics knowledge, its industrial application and 
its therapeutic potential. Sometimes those interests may overlap, on 
other occasions they may be completely incompatible. It is the 
political function of both the state and the supra-state regulation of 
human genetics to find a way of negotiating, and hopefully 
resolving, the tensions between the different interests. In so doing, 
the regulatory institutions concerned face an array of shifting 
political forces which place conflicting demands on the apparatuses 
of governance in terms not only of the outputs required but also the 
means by which these outputs are achieved. The legitimacy of the 
policy process itself – that is, the way in which policy is produced 
through agenda setting, formulation, implementation and evaluation 
– may be called into question.’
28 
 
Thus as governments attempt to foster processes for resolving debates rather than 
issues, policy processes as well as policy outcomes are likely to be contested. As this 
happens, space is created for new policy networks/communities to arise and pursue 
particular agendas. One example that has been cited is the rise of bioethics in EU 
policy-making—as science-based governance (and risk assessments) has been 
increasingly challenged, a ‘new transnational policy network’ of bioethicists 
emerged, and groups such as the European Group on Ethics in Science and New 
Technologies (EGE) are now part of the institution of biotechnology policy 
making.29 
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There is, however, another layer of complexity to be added to the consideration of 
governance as it relates to the web of concerns raised by the advance and application 
of the new genetics. In the wake of scientific controversies surrounding topics such 
as BSE, GMOs or MMR vaccines, the scientific authority of ‘expert’ institutions has 
diminished, leading, so it has been argued, to crises of public trust in key institutions 
of governance.30  
 
Previously, a common argument made by such governance institutions was that the 
public, if it properly understood science, would embrace rather than reject new 
technologies like GM crops. This viewpoint (resting on the so-called ‘deficit model’) 
has been rejected by those who insist that the public does not simply or typically 
misunderstand science, but rather assesses it by reference to a variety of different 
frames of meaning31—and not just by reference to the ‘meaning of risk as defined by 
science’.32 Against the deficit model, it is now commonly asserted that public 
ambivalence towards new technologies is neither necessarily nor typically the result 
of misunderstanding or wilful rejection, but of alternative concerns and modes of 
appraisal. 
 
This perspective has been influential. Governments and social scientists alike have 
recently spent much energy arguing for and exploring means of ‘opening-up’ policy-
making to the public.33 A prominent example is the UK government’s GM Nation? 
exercise, which was intended to provide one of three strands of evidence to 
contribute towards decisions on whether or not to commercialise GM crops—its 
stated objective was to ‘improve the evidence-base, and to create a dialogue between 
all aspects of opinion on GM.’34 
 
Importantly, despite its intentions, GM Nation? has been criticised for failing to 
achieve its objectives. According to one commentary, the debate did not so much 
engage the public, as attract a small and unrepresentative sample of campaigners.35 It 
was, according to another appraisal, largely ignored by the wider population.36  
 
The House of Commons’ Select Committee on Environment, Food and Rural Affairs 
(EFRA) questioned the depth and seriousness of the good intentions which were said 
to have led to the exercise: ‘the Government…must allay the suspicion that, having 
agreed to undertake a public debate, it did as little as it could to make it work.’37 The 
Committee is not alone in harbouring this suspicion, and there has been a more 
general concern that although governments acknowledge the importance of 
understanding public attitudes to new research and fostering public discussion of the 
deployment of new technologies, in practice they continue to employ the deficit 
model.38 Whether public engagement will emerge as a ‘rhetorical concession’39 or a 
significant transformation of biotechnology governance remains to be seen. 
 
Consequently, core questions for the future application of genomics and genomic 
technologies are these: what system of governance will emerge to shape the 
development of this field? Which actors will be influential within this (undoubtedly 
complex) system? How will scientific expertise and public understandings be 
accommodated? And what particular challenges may genomics itself pose to 
emerging or established patterns of governance? 
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One particular challenge is likely to concern the boundaries, for example, between 
individual and public health, and the responsibilities for each. It is often noted that 
the new genetics may lead to the framing of what can be thought of as public health 
issues (such as heart disease) as individual problems (albeit that individuals may then 
be deemed to have a public duty to ascertain their genetic risks).40 Yet, 
paradoxically, the identification and characterisation of individual risks may well 
depend on public screening programmes or on vast public projects of data gathering 
(such as UK Biobank). How will systems of governance manage the borders of 
public and private interest? If citizens are ambivalent towards scientific authorities, 
how likely are they to participate in or endorse genetic-based public health 
programmes, particularly when commercial interests are often perceived to be 
driving forces behind such programmes?41 Are present practices of informed consent 
sufficiently robust to cope with the particular challenges of gathering and using 
genetic data, and to protect individuals against the state or corporations? And can 
such protection be achieved without loss to the public goods which are at stake in 
public health measures or programmes? 
 
Summary of UK-based Research Addressing Governance, Policy, Publics and 
Genomics 
 
The governance of existing and emerging genetic technologies, and the way in which 
(and degree to which) these technologies are forcing governance systems to adapt, is 
the focus of significant attention.42 Some of these projects are focussed on 
describing, mapping and/or understanding the evolving governance systems relating 
to existing and new genetic technologies, such as stem cells, GMOs and 
pharmacogenomics.43 This may involve focussing on changing patterns in networks 
of governance and how they might influence regulatory standards.44 
 
As discussed earlier, public trust, engagement and understanding of science are 
critical to analysis of governance, genomics and public policy. The projects focussed 
on these issues45 underscore this point in examining, for example, ‘how far scientific, 
expert-driven risk assessment techniques can be reconciled with deliberative 
approaches to public consultation’.46 Thus an appreciation of public understandings 
or perceptions of risk is important, and this has been the focus, from varying 
perspectives, of significant research.47 Equally important are assessments of various 
public engagement techniques, a key element of research examining the social 
dynamics of stem cells.48 
 
Public understandings of risk also tie-in with research into public understanding of, 
and attitudes towards, different aspects of genetic medical services and initiatives. 
One project argues that people’s notions of citizenship, consumption and expertise 
will inform a fresh understanding of ‘genetic subjecthood’, and thus, it is hoped, 
contribute to more informed and sensitive policy-making.49 Similarly, the views of 
different patient groups (e.g. people receiving pre-implantation genetic diagnosis or 
IVF treatments50) are expected to ‘provide practical feedback to clinical scientists, 
practitioners, and policy-makers concerned with genetic and reproductive 
medicine’.51 To this end, a few projects run through the ESRC Innovative Health 
Technologies programme have demonstrated that clinical/professional and ‘lay’ 
understandings of risk produce interpretations which may overlap but are also 
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divergent.52 Such findings draw attention to, for example, the need for careful 
consideration of how genetic counselling is conducted.53 Meanwhile, as it has been 
commonly argued, there may be benefits to ‘opening’ science to publics at earlier 
stages. Thus patient attitudes to genetic testing, for example, may usefully inform an 
algorithm to help physicians prescribe safe dosage of warfarin, which is the focus of 
social research studying pharmacogenetics.54 
 
As previously mentioned, the emergence of bioethics is an influential aspect of 
contemporary governance of the ‘new genetics’ and thus as an important element in 
policy-making. Indeed, a Europe-wide project with its UK base at Cesagen is 
examining the institutionalisation of ethics in science policy.55 Various other projects 
are specifically and varyingly focussed on ethical and governance issues arising from 
genetic research and services.56 
 
A central norm of much recent bioethics has been that of ‘informed consent’, and the 
understanding and application of this norm is likely to be central to the future 
governance of medical interventions emerging from or advanced by genomics. 
Projects have explored social and ethnic differences to consent and the problems 
posed by practices of individual consent to procedures which yield information 
which may be of familial significance.57 Views and preferences relating to the very 
specific problems around consent and other aspects of genetic research involving 
children in the UK are also being investigated.58 Similarly the specific problems 
raised for procedures of consent outside the cultural context in which they have 
arisen are a concern.59 An analysis of how non-professionals understand bioethics 
may help to address whether, and how much, significance the public places on 
consent as compared to the discipline of bioethics or current systems of clinical 
governance.60 
 
(iii) Regulation, Innovation and Genomics 
 
Globalisation and governance (as against government), provide the context for both 
the regulation of genomics and its related technologies, and for further innovation in 
this field. Of course the choices that a society makes about governing new 
technologies are often manifested in the regulatory arena, and these choices are 
subject to myriad potential conflicts of objectives or interests, such as between 
ensuring consumer safety or promoting national economic competitiveness. The 
regulation of technologies, then, becomes a key area of controversy (and 
consequently of social science research): ‘Governance in its regulatory form is the 
political theatre where the pressures for change from the arenas of science and 
industry meet the inchoate needs, values and sensibilities of civil society.’61 
 
Consumer groups, environmental groups, public health activists, patient advocacy 
organisations, industry and science all attempt to influence, shape or determine 
regulatory outcomes. Importantly, however, these groups influence more than 
regulation of new technologies; the socio-political environment they create also 
shapes the trajectory of new technologies: 
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‘Assessing the ‘impact’ of a new technology cannot…be simply 
separated from either the process of technical innovation or debates 
about public policy. The way in which social problems are 
anticipated and resolved influences the behaviour of actors, such as 




Regulation and innovation, therefore, are intrinsically linked. Understanding the 
processes influencing one will also contribute an understanding of the other. Both, 
from varying perspectives, have been the focus of substantial research. 
 
Regulation & Genomics 
 
One thing regulatory regimes seek to regulate is risk. Biotechnologies in general 
(and those which may emerge from the further development of genomics) are 
centrally associated with the modern risk environment as Giddens characterised it, 
which is ‘structured by humanly created risks.’63 What is significant about these new 
risks from biotechnology, however, is that in a variety of ways they test and 
challenge existing regulatory regimes. 
 
It is the case, of course, that these technologies may pose risks to the environment 
and risks to human health which are, in a manner of speaking, quite familiar to 
regulatory regimes. But this is not always the case. Some risks which may emerge 
from genotyping (e.g. the genetic risk of, or susceptibility to, breast cancer) are quite 
difficult to conceptualise, express and handle. Other risks may be introduced by 
biotechnologies (such as gene flow from GM crops) and not straightforwardly 
estimated or assessed. Such risks may not only create new uncertainties. They may 
also transcend the jurisdictions of existing regulatory institutions, creating the need 
for new forms of expertise as well as regulatory agencies.64 All this occurs in the 
wider context described in III (ii), in which, so it is commonly argued, the public has 
lost trust in traditional institutions of governance, not least the scientific authorities. 
This web of uncertainty around risk has created what Brown & Michael have called 
‘meta-risks’—‘the social and political risks that are incurred when decisions are 
made about how to go about assessing technical risks.’65 
 
Jasanoff has argued that technical decision-making often incorporates socially or 
politically contingent judgements, such as those concerning appropriate levels of 
risk.66 This is concealed, however, by the maintenance of a false boundary between 
‘science’ and ‘policy’ with the result that there remains little room for accountability 
and public scrutiny.67 The USA’s Food & Drug Administration, as with other 
agencies, has maintained this boundary, so she argues, in order to ‘harness the 
authority of science in support of its own policy preferences.’68 
 
Insofar as the new biotechnologies have exposed the significance and depth of 
uncertainties surrounding risks and their assessment, there may be a new and robust 
awareness of the role of values and interests in shaping ‘regulatory science’. 
However that may be, new and emerging biotechnologies will pose afresh the 
questions this section has introduced: How are regulatory issues framed? How is 
‘science’ or ‘evidence’ used in regulatory decision-making? How are regulatory 
systems evolving to cope with new biotechnologies? How are stakeholders 
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organising in order to attempt to influence regulation and where are the boundaries 
between experts and non-experts drawn? 
 
Innovation and Genomics 
 
As discussed earlier, regulatory policies, and the multitude of actors attempting to 
influence them, shape the trajectories of new technologies. More generally, it is 
essential to recognise that innovation does not happen in isolation. Rather, it occurs 
in so-called sociotechnical systems in which social actors both shape and are shaped 
by technologies,69 and thus in the context of the issues of globalisation and 
governance. 
 
Some actors promote the notion of a ‘biotechnology revolution’70 which is to be 
accepted and embraced. In the case of genomics and genomics-related technologies, 
potential social problems and risks which they may bring are reckoned by these 
advocates to be outweighed by the substantial potential benefits to society which 
they are said to offer. Government and industry have become strong advocates of 
biotechnology and link it to national wealth: agencies such as the UK Government’s 
Department of Trade and Industry (DTI) emphasise the strategic importance of 
domestic biotechnology industries through funding publications such as ‘Bioscience 
2015: Improving National Health, Improving National Wealth’.71 In another report, 
‘Genome Valley: The Economic Potential and Strategic Importance of 
Biotechnology in the UK’, the DTI argues: 
 
‘It will be important for Government to continue…to take action to 
ensure that entrepreneurial, fiscal and regulatory frameworks are 
set in a way which makes the UK the chosen location for major 
internationally mobile investments in biotechnology.’
72 
 
This report stressed the necessity of a ‘balanced regulatory regime’73 but also 
addressed additional important factors influencing innovation, such as intellectual 
property rights, infrastructures fostering innovation (e.g. biotech clusters) and 
academic spin-out companies. These are all areas that have been the focus of policies 
to stimulate innovation in biotechnology. 
 
Yet despite (or perhaps because of) the intensive emphasis placed on fostering 
innovation in biotechnology, an increasing number of observers are questioning the 
biotechnology ‘revolution’—it seems clear that, to date, there have been far fewer 
new genomics-based products than originally expected.74 The dearth of new products 
puts additional pressure on a pharmaceutical industry that had already been 
undergoing a significant transformation due to such factors as changing regulatory 
environments, negative publicity, and the patent expiration of many profitable 
products.75  
 
With industry facing such pressures in the more lucrative markets, the question of 
how to stimulate innovation that will benefit developing countries remains critical. 
As WHO has argued, global research is determined by the markets of wealthy rather 
than developing countries.76 If markets cannot be counted on to develop drugs sorely 
needed by developing nations, then other mechanisms may be necessary if 
innovation is to serve the needs of the developing world and prevent the further 
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exacerbation of inequalities. Among the possible mechanisms, the following are 
prominent: private-public partnerships, dedicated funds for research and 
development, tax incentives, differential drug pricing and more equitable usage of 
intellectual property rights.77 
 
In summary: how and why new technologies are regulated closely relates to 
underlying beliefs about how societies should be organised.78 As such, discussions 
about regulation often comprise the focal point for controversy and contestation 
amongst actors with competing and conflicting interests and objectives. Regulatory 
systems are also one of the forces shaping and being shaped by innovative new 
technologies. Since governments and industry have invested large sums to ensure that 
domestic biotechnology industries can contribute to national and international health 
and wealth, both regulatory systems and the way in which innovation is promoted 
have been, and will continue to be, key subjects for social science research. 
 
UK Research Addressing Regulation, Innovation and Genomics 
 
Some of the UK-based projects studying risk governance, as one aspect of 
regulation, have already been described. In particular reference was made to projects 
focussed on examining the influence of various stakeholders in shaping regulatory 
systems relating to specific biotechnologies.79 Other research seeks to understand the 
development of regulatory systems as they cope with issues thrown up by research 
informed by the new genetics, such as xenotransplantation or fetal stem cells.80 
Regulatory institutions themselves may play a role in ‘stabilising’ new technologies, 
and this is also the focus of research examining institutions like stem cell banks.81 
 
The dynamic interrelationship between innovation and regulation has been the 
subject of work in the sociology of expectations.82 Specifically in relation to stem 
cells, the project will consider how expectations of the application of technology—
expectations held by academia, industry and government—shape not only the 
development of the technology, but also of perspectives and attitudes towards its 
regulation. Plainly, if expectations of the potential ‘goods’ of a technology are 
overstated, this might lead regulators to accept undue risks. Thus, study of the nature 
and character of risk assessment of, for example, pharmaceuticals is a key area of 
research contributing to a better understanding of unfolding patterns of regulation 
and innovation, and so to an understanding of how a medical technology may or may 
not diffuse from the ‘bench to bedside’.83 One such new technology or approach 
which is the subject of considerable expectation is pharmocogenomics, and the 
uptake of new diagnostic-based therapies based on pharmocogenomics is the focus 
of research that will look in particular at similarities and differences in regulatory 
assessment in the US, Europe and Japan.84 Meanwhile, additional research is 
analysing the influence of regulatory agencies on the development of pharmaceutical 
products, and, more broadly, some research is considering whether public 
accountability and commercial success can be reconciled by regulatory systems.85 
 
Finally, a wide range of research is studying the factors influencing innovation 
within industry, and the nature, direction and management of such innovation. 
Some86 are focussed on the impact of genomic and post-genomic technologies on 
innovation within industry while others87 are studying trends in patenting and how 
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they relate to public policy and innovation. Others yet are focussing on the influence 
of various factors on academic and industrial research and development, such as 
clustering, multidisciplinary interactions or the broader macroeconomic 
environment.88 
 
Part IV - Directions for Future Research 
 
As the social science research described in Part Three proceeds, the Genomics 
Forum has had the opportunity, as a newer part of the UK landscape, to take a step 
back and consider the overall direction of this research. In doing so, three broad and 
related areas are identified as providing important ground for future engagement. 
(i) The first area, taking note of the context in which much current social science 
research is located, involves a clarification of the nature of the contribution of social 
sciences to policy-making in genomics. 
(ii) The second area is related to issues which arise from the first, and involves social 
science in the further development of, and participation in, inter-disciplinary projects 
addressing central policy questions, working with, for example, law and economics. 
(iii) The third area, whilst noting the importance of policy questions, also notes the 
constraints which a focus on questions of immediate policy significance can place on 
social science, and involves the development of wider social scientific reflection on 
the meaning of genomics and post-genomic science for human self-understanding. 
 
(i) The Context or Framing of the Social Science of Genomics 
 
The contribution of social science to understanding the significance, implications 
and consequences of the rise of genomics is being made in intimate connection with 
the intellectual contribution of other disciplines, and chiefly in connection with the 
contributions of ethics and law. This connection was formalised in terms of funding 
by the decision of the Human Genome Project to devote a proportion of its vast 
resources to a stream of work on ethical, legal and social aspects of the sequencing 
of the genome. This formal linking of different disciplines and research interests is 
reflected in the acronyms ELSA (for ethical, legal and social aspects) or ELSI 
(ethical, legal and social implications), which are now accepted shorthand for 
referring to a range of non-scientific questions posed by science and technology. 
 
That social science is operating in this context is highly significant in considering the 
framing of an agenda for future research. Whilst the linking of social science with 
ethics and law has been appropriate in certain ways, it is possible that this same 
linkage has threatened to conceal the particular contribution that social science 
properly makes to the field. There is a danger that the invention and institutionalising 
of work on ELSA/ELSI of genomics, has hidden rather than highlighted the 
contribution of the social sciences. Certainly, and at the very least, it is noticeable 
that bioethics has tended to dominate the framing of the ELSA/ELSI agenda. 
 
It is important, therefore, for social science not simply to accept this situation as 
given, but to take steps to clarify its disciplinary integrity and its interdisciplinary 
relationships. In the context of the ‘ELSA/ELSI-fication’ of the critique of science, 
in the future, such steps will be a vital element in securing a proper hearing for the 
subject in the future in the policy arena. What is needed, therefore, is an attempt to 
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clearly state the nature of social science’s contribution to the understanding and 
analysis of genomics and to clarify the particularity of this understanding by placing 
alongside it accounts from philosophy and law. But these discrete statements would 
not be enough. The framing of the contribution of social science in ELSA/ELSI 
programmes demands systematic thinking not only about the specific contribution of 
the social sciences, but also an attempt to describe how the social sciences 
complement (or challenge) the other elements which have become institutionalised 
partners in the policy debate.89 
 
(ii) Social Science and Interdisciplinarity in Genomics 
 
The political reality of the ELSA/ELSI context currently demands that the social 
sciences work with and alongside other disciplines to ensure that the social sciences’ 
particular insights and concerns are acknowledged. Two areas that seem worthy of 
further attention by social scientists, are those concerning intellectual property 
regimes and the evaluation of genetic services/interventions in the field of human 
health. These two areas are central to the development and application of genomic 
science and as such are deserving of continued critical attention from the social 
sciences. 
 
It is a familiar point that different regimes for the protection of intellectual property 
will have crucially different consequences for the course of innovation, research and 
development—and not only ‘development’ in the R&D sense, but in the sense of 
‘international development’. But equally significant for the course of development of 
genomic science are choices relating to the recognition and protection of intellectual 
property, and both national and international budgetary decisions regarding which of 
the applications of genomic science to human health receive funding. As the 
previously cited WHO Report (Genomics and World Health) makes clear, critical 
questions will need to be addressed to the claims of genetic medicine for scarce 
health resources in developing economies; but the same evaluative questions will 
have to be asked by any system of health provision in which there are competing 
claims for health resources. Thus the NHS will have to ask what priority in funding 
should be given to the new possibilities opened up by genomics for Pre-implantation 
Genetic Diagnosis (PGD), or to so-called ‘personalised medicine’ based on 
pharmocogenomics, or to individual or population genetic screening or testing. The 
answers to these particular questions are in and of themselves highly significant, and 
like the answers to questions about the merits of different regimes of protection for 
intellectual property, have the added significance of shaping the equally socially 
important development path of a whole raft of new technologies. 
 
If the framing of the larger ELSA/ELSI debate should be subject to critical 
questioning, so too should the detailed treatment of individual policy questions 
within the agenda. If the first requires that social science itself stand back from the 
entire debate and seek to clarify its disciplinary integrity and its interdisciplinary 
relationships in a theoretical way, the second circumstance requires that social 
science should seek to develop interdisciplinary work and relationships in key areas, 
such as in relation to the questions concerning the nature and form of regimes for the 
protection of intellectual property and the evaluation of genetic services or 
interventions. 
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(iii) The Meaning of Genomics and Post-Genomic Science for Human Identity 
 
Marc Quinn’s portrait in the National Portrait Gallery of Sir John Sulston, Nobel 
laureate in Physiology or Medicine, posed starkly the issues of genetic or genomic 
essentialism. Quinn’s portrait is simply the analysis of Sulston’s DNA on jelly in a 
plate. Is John Sulston, so this portrait seemed to ask, this particular DNA sequence? 
Whilst in the rest of the Gallery we would scrutinise the faces of the subjects in an 
endeavour to fathom or understand the person depicted (something we might attempt 
even in the event of our knowing nothing else of a person’s life or circumstances), 
this portrait seems to pose the question as to whether the person who is mysteriously 
and problematically present to us in his or her face, is properly present to us in his or 
her genome, once we have learnt to read it. 
 
Of course the move beyond genomics to proteomics and metabolomics is already, in 
effect, a repudiation of this genomic essentialism—we need to understand much 
more than the functions and interactions of genetic material, even in the totality of 
the genome, if we are to understand the biology of organisms. However that may be, 
it is nonetheless the case that genomics has served to reinforce the view which 
predates it, namely that genetic information is peculiarly personal or fundamental 
information and somehow goes to the heart of who we are. As well as affecting 
understanding of, and attitudes to, individual responsibility, genomic science and 
technology (in the shape of DNA profiling, for example) is increasingly being used 
to create, inform and shape categories of identity (such as race, ethnicity, sexuality, 
criminality and health status). Social science’s concern to contribute to the policy 
debate must be expressed, then, not only in its contribution to the discussion of 
questions of very immediate policy significance, but also in continuing to maintain a 
broader perspective of reflection on the meaning of genomics and post-genomic 
science for human identity and self-understanding. 
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